GLAUKOS Corp (GKOS)
GLAUKOS Corp (GKOS) from its SEC filings: 2025 revenue $507.4 million (+32% vs the year before), net margin -37%, free cash flow -$22.5 million. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Surgical & Medical Instruments & Apparatus |
| Revenue (2025) | $507.4 million |
| Revenue growth | +32% |
| Net income | -$187.7 million |
| Net margin | -37.0% |
| Free cash flow | -$22.5 million |
| Diluted EPS | $-3.28 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +50% |
| Cash | $114.5 million |
| Long-term debt | $765,000 |
| Share count, 1 year | +3% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.